) were performed at our institute. 22 patients refused biopsy. We investigated incidence and severity of PCa in 203 men diagnosed with hypogonadism (T 350 ng/dl). 42 men opted for and 162 against TRT. Biopsies were performed when indicated according to EAU guidelines.
INTRODUCTION AND OBJECTIVES: Androgen deficiency (AD) is common among aging males. Prior to starting androgen replacement, men with AD are recommended to undergo prostatespecific antigen (PSA) screening. However, given the lower prevalence of prostate cancer (PCa) in AD, it remains unclear whether PSA is a sensitive and specific test for detecting PCa and clinically significant PCa (csPCa) among AD men. Thus, we sought to evaluate the diagnostic properties of PSA to predict PCa and csPCa among men with AD compared to men with normal serum androgens.
METHODS: We conducted a retrospective analysis of 3,197 men undergoing a 2-year prostate biopsy in the placebo arm of the Reduction by Dutasteride of PCa Events (REDUCE) study. Men were divided in two groups based on the presence or absence of AD (total testosterone <10.4nmol/L). Diagnostic properties of PSA to predict PCa and csPCa defined as Gleason score ! 7 were determined for several PSA thresholds in the two groups and plotted as receiver operator characteristic (ROC) curves.
RESULTS: A total of 603 (18.3%) had AD. AD men had higher mean body mass index and prostate volume (both P<0.05) and comparable age, race, digital rectal exam, PSA levels, and family history of PCa. The prevalence of PCa and csPCa was 92 (15.3%) and 27 (4.5%), respectively, for AD men compared to 458 (17.0%) and 138 (5.1%), correspondingly, for non-AD men. The area under the ROC curve for PSA to predict PCa and csPCa in non-AD men was 0.60 and 0.70, respectively, and 0.65 and 0.68, correspondingly, in AD men ( Figure) . A ! 4.0 ng/mL PSA cutoff to predict PCa yielded a sensitivity, specificity, and correct classification of 87.3%, 20.7%, and 32.0%, respectively, in non-AD men and 91.3%, 22.3%, and 32.8%, correspondingly, in AD men. The same cutoff to predict csPCa yielded a sensitivity, specificity, and correct classification of 93.5%, 20.0%, and 23.8% in non-AD men and 92.6%, 20.8%, and 24.1% in AD men. CONCLUSIONS: In a cohort of men undergoing prostate biopsy, PSA had a similar sensitivity, specificity and accuracy to predict PCa and csPCa among AD men compared to their non-AD counterparts. PSA seems to be a safe means of PCa screening in men with AD. 
INTRODUCTION AND OBJECTIVES: Previous studies
showed that, besides diseases of the prostate, the intake of certain medication may influence the PSA level. In this study, we investigated the effect of common medication on the PSA level in more than 13,000 men. Furthermore, we aimed to assess the effect of low dose finasteride (1 mg) on PSA, as the use of 5 mg finasteride is known to affect PSA levels.
METHODS: We included 45-year-old men of the PROBASE trial between April 2014 and April 2017. A short anamnesis with documentation of current medication was conducted by a study physician. Most commonly prescribed medication was classified into metabolic (metformin, insulin, statins), cardiovascular (beta-blocker, thiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, angiotensin receptor blockers), and central nervous system agents. In a separate analysis, we investigated PSA levels of men receiving low dose finasteride therapy of 1 mg. PSA levels of each subgroup were compared with the PSA levels of the remaining sample (men without medication/comorbidities) via Wilcoxon test.
RESULTS: PSA levels of 13,021 subjects were analyzed. Median PSA level was 0.7 ng/ml (IQR: 0.5-1.1). Use of metabolic and cardiovascular agents, metformin, insulin, and ACE inhibitors were associated with 20%, 14%, and 7% (all p<0.01) lower PSA levels, respectively. Use of central nervous system agents was not associated with a change in PSA level. Low dose finasteride therapy (1 mg) was associated with a median decrease in PSA level of 31% (p<0.001).
CONCLUSIONS: Our study shows that the intake of metformin, insulin, and ACE inhibitors is associated with a lower PSA level. Use of statins, in contrast to previous studies, did not result in a decrease in PSA concentrations whereas low dose finasteride therapy (1 mg) for male androgenetic alopecia was associated with a lower PSA level. Therefore, we suggest applying the same recommendations for interpretation of a PSA test in men receiving 1 mg/day finasteride, as we do for men receiving 5 mg/day finasteride.
